FRM
KROS icon

Fox Run Management’s Keros Therapeutics KROS Stock Holding History

Fox Run Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,790
Closed -$243K – 1127
2026
Q1 		$243K Sell
22,790
-2,890
-11% -$44.6K 0.04% 693
2025
Q4 		$523K Buy
+25,680
New +$451K 0.08% 481
2025
Q3 		– Sell
-12,354
Closed -$165K – 1087
2025
Q2 		$165K Sell
12,354
-6,635
-35% -$89.6K 0.03% 771
2025
Q1 		$193K Sell
18,989
-3,224
-15% -$37.4K 0.03% 803
2024
Q4 		$352K Buy
22,213
+16,069
+262% +$835K 0.06% 568
2024
Q3 		$357K Buy
+6,144
New +$303K 0.08% 485

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Fox Run Management's KROS Position: Q2 2026 in Review

Fox Run Management sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 22,790 shares — an estimated $243K sold.

Fox Run Management first reported a position in KROS in Q3 2024 and held it in 6 quarters. The position peaked at $523K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Fox Run Management reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 22,790 Keros Therapeutics shares in Q2 2026, an estimated $243K.
  • Fox Run Management first reported a position in Keros Therapeutics in Q3 2024 and held it in 6 quarters.
  • Fox Run Management's Keros Therapeutics position peaked at $523K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.